Hybrid Neuroblastoma Scores v1.0
Research type
Research Study
Full title
Evaluation of Hybrid Semi-Quantitative Scores for Neuroblastoma
IRAS ID
221480
Contact name
Hugh J Wallace
Contact email
Sponsor organisation
NHS Greater Glasgow and Clyde
Duration of Study in the UK
1 years, 0 months, 1 days
Research summary
This study aims to evaluate the impact of fused single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI) on existing semi-quantitative scores for high-risk Neuroblastoma, a type of paediatric cancer with a poor progonosis.
Within the literature Neuroblastoma scores have been shown to correlate with patient outcome, so can be used to provide a method of risk stratification. However they are limited to use with only planar scinitigraphy. Modern nuclear medicine makes extensive use of 3-dimensional scintography with SPECT, hybrid imaging with SPECT/CT, and fusion with other modilities such as MRI. These techniques provide improved lesion detection over planar imaging and therefore should offer more accurate scores and more accurate patient stratification. To date no group has examined the impact of these techniques on Neuroblastoma scores.
This study will assess the impact of fused SPECT/MR on the two main Neuroblastima scoring systems; the Modified Curie Score and the SIOPEN Score. It will use already existing data at the Royal Hospital for Children in Glasgow, where fusion of SPECT and MRI has been undertaken routinely over the last 5 years. Randomised blinded scoring will be performed by a number of Radiologists and Nuclear Medicine Physicians. This methodology is designed to assess the differences in total score due to SPECT/MR across a range of treatment time points, and to assess the difference in score reproducibility with the addition of SPECT/MR.
REC name
East Midlands - Nottingham 1 Research Ethics Committee
REC reference
17/EM/0142
Date of REC Opinion
12 Apr 2017
REC opinion
Favourable Opinion